Ovid Therapeutics Inc.

NASDAQ:OVID

Biotechnology

Healthcare
$2.26 -4.34%

-$0.11 today

Market cap
$426.53M
Beta
0.18
P/E (TTM)
-7.1
EPS (TTM)
-$0.33
52W Low $0.29High $3.11

Volume 2.16M

Average 3.07M

OVID Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Ovid Therapeutics Inc.NASDAQ: OVID

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures outflow grows to $0

Q1 FY2026 capital expenditures was $0, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was $0.

Context

  • Capital expenditures amounted to 0.0% of revenue in FY2025, down 12.5 pp from a year earlier.
  • Capital expenditures increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0+100.0% YoY
LTMMar 2026
$0+100.0% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
+100.0%

Capital Expenditures vs competitors

How OVID compares with its peers on the latest reported figures

  • OVID's LTM Mar 2026 capital expenditures of $0 is the smallest of the 11 companies compared; the peer median is $926.5K.
  • Its year-over-year change of +100.0% is the 6th highest of 11, against a peer median of +81.5%.
  • Capital expenditures amounts to 0.0% of revenue for OVID, versus a peer median of 5.3%.
OVID Competitors Peer median
Capital Expenditures for OVID and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGTXMeiraGTx Holdings plcLTM Mar 2026$10.62M +113.0%-56.0%13.3%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$9.32M +140.4%-65.5%1.4%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$7.51M +140.5%+294.4%51.6%
TSHATaysha Gene Therapies, Inc.LTM Jun 2026$3.38M +718.6%-69.0%61.6%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$1.95M -4.2%+1.4%5.3%
WVEWave Life Sciences Ltd.LTM Mar 2026$981.99K +43.1%-19.2%1.4%
STOKStoke Therapeutics, Inc.LTM Mar 2026$871K +153.9%-44.7%2.7%
NGNENeurogene Inc.LTM Mar 2026$669.4K -56.0%-19.0%—
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$432K +50.0%-23.9%—
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$169K -96.0%-62.9%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$0 +100.0%—0.0%
Peer median (excluding OVID) $926.5K+81.5%-34.3%5.3%

Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income119.84M(54.17M)(52.34M)(26.43M)(17.41M)
Depreciation & Amortization237K1.38M1.6M613K273K
Deferred Income Tax00000
Stock-Based Compensation06.56M7.29M6.28M4.81M
Change in Working Capital(16.81M)(8.23M)2.39M(150K)(4.1M)
Accounts Receivables141.76K0000
Inventory00000
Accounts Payables1.7M(5.17M)1.75M(512K)(1.23M)
Other Working Capital(18.66M)(3.06M)635.51K362K(2.87M)
Other Non-Cash Items15.35M(764.94K)(4.71M)(36.26M)(21.9M)
Operating Cash Flow118.61M(55.23M)(45.78M)(55.96M)(38.33M)
Capital Expenditures(189.41K)(1.42M)(137.46K)(71K)0
Acquisitions (Net)(1.63M)(2.5M)(10M)00
Purchases of Investments(1.63M)(172.96M)(112.44M)(73.25M)(91.85M)
Sales of Investments090M120M128M42M
Other Investing Activities(5.4K)(1M)(97.15K)(89K)0
Investing Cash Flow(1.82M)(87.88M)(2.58M)54.59M(49.85M)
Debt Repayment0030M00
Common Stock Issued925.4K180.66K535.2K622K75.21M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(21.31K)0000
Financing Cash Flow904.08K180.66K30.54M622K75.21M
Effect of Forex Changes(1.93M)000(167K)
Net Change in Cash115.76M(142.93M)(17.83M)(740K)(13.15M)
Free Cash Flow118.42M(56.65M)(45.92M)(56.03M)(38.33M)

Ovid Therapeutics Inc.

NASDAQ:OVID

Intrinsic Alpha fair value

Locked

Current Price

$2.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.